Advanced or metastatic solid tumors: research hub
9 indexed studies · 8 currently recruiting
- recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
This study is looking at treatments for different advanced cancers like breast, stomach, and lung cancer. It’s testing a new medicine called nivolumab, alone or with another drug, ipilimumab, to see how well they shrink tumors and if they have side effects.
Germany - recruitingHuman Pharmacology (Phase I)- Other
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
This study is looking for the best dose of a new medicine called BI 907828 (brigimadlin) for people with advanced cancers that have grown or spread. It's an early-stage study to understand how the medicine works in the body.
Spain · Belgium · Sweden - recruitingHuman Pharmacology (Phase I)- Other
A Drug Absorption Study of MK-3475A in Participants with Solid Tumors
This study looks at how a new medicine, MK-3475A, is absorbed by the body in people with advanced solid tumours. It aims to understand how the drug works and how much gets into the bloodstream. Participants will be adults, male or female, aged 18 and over.
Spain · Hungary - recruitingTherapeutic exploratory (Phase II)
A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients with Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)
This study is testing a new medicine, ART0380, for people with advanced cancers that have spread. Researchers want to see if this medicine can shrink tumors or stop them from growing. It's an early-stage study to learn more about how well it works and if it's safe.
France · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab, in Patients With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, BGB-30813, sometimes with another drug called tislelizumab, for people with advanced cancers. Researchers want to see if it's safe, how it works in the body, and if it could help fight cancer.
Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
This study is looking at a new medicine called BGB-A3055, sometimes given with another medicine called tislelizumab. It's for adults with advanced cancers. Doctors want to see if it's safe, how the body handles it, and if it could help fight cancer.
France - recruitingPHASE1
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This study is testing a new medicine called IPH4502 for advanced cancers. It aims to see how safe it is, what side effects it might cause, and if it could help people whose cancers have a specific marker called Nectin-4.
United States · France - recruitingPHASE1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
This study is testing a new medicine called DAY301 for advanced cancers that have spread. It aims to see how safe it is, what side effects it causes, and if it can help shrink tumours. It's an early-stage study.
United States · Canada - active not recruitingPHASE1
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
This study is testing two medicines, Naporafenib and Trametinib, together for certain advanced cancers. It's for people whose cancer has a specific change called RAS Q61X, and who haven't responded to other treatments or have limited options.
United States · Australia · Canada